Non-fatal overdose among people who inject drugs in England: 2017 report. by unknown
  
Non-fatal overdose among people who 
inject drugs in England: 2017 report 
 
Data from the Unlinked Anonymous 
Monitoring Survey of HIV and Hepatitis in 
People Who Inject Drugs 
 
Health Protection Report 
Volume 11 Number 39 
3 November 2017 
 
 
 
Non-fatal Overdose among People Who Inject Drugs in England: 2017 report 
Health Protection Report  Volume 11 Number 39 
 
2 
Non-fatal overdose among people who 
inject drugs in England: 2017 report 
Overdose poses a significant risk among people who inject drugs (PWID) and is a major cause 
of mortality [1]. There has been a notable rise globally in overdose deaths, with the US reporting 
a  tripling from 1999-2017 [2], alongside significant increases in Australia and Canada [3-6]. 
Whilst the UK has a lower rate of overdose deaths than the US, it is higher than the rest of 
Europe, and there have been similar increasing trends in overdose deaths in recent years [7-
10]. Considerable investigation and response into the extent of these trends has occurred [11], 
however there is limited data available for non-fatal overdose in the UK. To address this, the 
Unlinked Anonymous Monitoring (UAM) Survey [12] included questions on overdose and 
naloxone use in 2013. This report presents the data from 2013-2016 on self-reported non-fatal 
overdose among PWID. 
 
Background on overdose deaths 
Opioid overdose, often heroin, can be due to the variety and limited awareness of the drug 
purity being consumed [8,13,14]. Overdose is also associated with polysubstance use where 
the additional use of alcohol or benzodiazepines alongside heroin increases the depressant 
effect [8]. Concurrent stimulant use (for example cocaine) can mask the depressant effect 
resulting in higher heroin use which increases the likelihood of overdose [1].  
 
In 2016, the highest figure of 2,383 on record was registered of drug misuse deaths in England; 
a 3.6% increase on the previous year [15]. Since 2012 heroin related deaths in England and 
Wales have more than doubled. The largest increase in drug misuse death rates in England and 
Wales is among those aged 40-49 (73% increase from 2012-2016) [10], a trend consistent with 
the ageing population of  PWID [15]. The ageing cohort of heroin users is one of the factors 
identified as a cause of the rise in drug related deaths, due to deteriorating general health and 
increased susceptibility to overdose [15].  
 
Naloxone is an opioid-antagonist which temporarily blocks opioid receptors and reverses 
respiratory depression and sedation. With training, naloxone can be safely administered as the 
emergency antidote for opiate overdoses [8,16]. UK regulations in 2015 increased the 
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availability of naloxone to be supplied by drug treatment services without a prescription, and to 
extend to family, friends and peers of those at risk [17,18]. 
 
Non-fatal overdose among PWID 2013-2016 
Among the participants  who took part in the main Unlinked Anonymous Monitoring Survey 
across England in 2016 who had injecting during the preceding 12 months (recent injectors), 
19% reported overdosing in the preceding year, which has increased significantly from 15% in 
2013*. Overdose reporting increased significantly among those aged 25 to 34, from 13% in 
2014 to 23% in 2016**; although it should be noted that the number of younger injectors are 
declining so this finding merits cautious interpretation. In 2016 there was no difference by 
gender in those reporting overdose (table 1).  
 
There was a higher level of overdose reported among those who had recently initiated injecting  
(i.e. those who began injecting in the preceding three years) in 2013 than those who have been 
injecting for longer than three years (21% vs14%). However in 2016, overdose was similar 
among those who had been injecting for longer and those who had started in the preceding 
three years (19% vs 18%) (table 1). 
 
Self-reported overdose in 2016 was lowest among those who were currently in treatment for 
their drug use (i.e. those being prescribed a detox or maintenance drug regime; 16%). Self-
reported overdose was 21% among PWID who had never been in treatment in 2016, and was 
especially high among those who had previously been in treatment but were not currently (31%) 
(table 1) 
 
 
 
 
 
 
 
 
* After adjusting for age and gender in a multi-variable analysis, the adjusted odds ratio for 2016 vs. 2013 was 1.4 
[95% CI, 1.1-1.6]; indicating a significant increase in the level of self-reported overdose in England between these 
two years. 
** After adjusting for gender in a multi-variable analysis, the adjusted odds ratio among those aged 25-34 years for 
2016 vs. 2013 was 2.0 [95% CI, 1.5-2.7]; indicating a significant increase in the level of self-reported overdose in 
England between these two years. 
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Table 1. Self-reported overdosing in the last year among recent injectorsa by gender, age, 
time since first injected and treatment status; England: 2013-2016 
Year 2013 2014 2015 2016 
All 
Proportion overdosing in preceding year 15% 17% 18% 19% 
Number overdosing in preceding year 282 291 277 324 
Total number answering question 1,851 1,763 1,567 1,676 
Gender 
Male 
Proportion overdosing in preceding year 16% 16% 19% 19% 
Number overdosing in preceding year 217 215 219 240 
Total number answering question 1,390 1,322 1,166 1,240 
Female 
Proportion overdosing in preceding year 14% 17% 15% 19% 
Number overdosing in preceding year 64 75 58 82 
Total number answering question 449 437 399 432 
Age 
Under 25 
Proportion overdosing in preceding year 24% 23% 24% 23% 
Number overdosing in preceding year 30 27 17 10 
Total number answering question 127 118 71 43 
 25 to 34 
Proportion overdosing in preceding year 13% 19% 21% 23% 
Number overdosing in preceding year 95 113 106 120 
Total number answering question 715 609 513 511 
35 to 44 
Proportion overdosing in preceding year 15% 15% 15% 16% 
Number overdosing in preceding year 105 110 98 115 
Total number answering question 724 710 644 719 
45 and over 
Proportion overdosing in preceding year 17% 11% 17% 20% 
Number overdosing in preceding year 45 35 55 75 
Total number answering question 263 306 330 384 
Time 
since 
first 
injected 
≤3 years  
(recent 
initiates) 
Proportion overdosing in preceding year 21% 20% 22% 18% 
Number overdosing in preceding year 44 35 37 25 
Total number answering question 211 176 168 140 
>3 years 
Proportion overdosing in preceding year 14% 16% 17% 19% 
Number overdosing in preceding year 221 243 235 290 
Total number answering question 1,580 1,541 1,359 1,495 
Treat-
mentb  
status 
Never in 
treatment/ 
not known 
Proportion overdosing in preceding year 16% 13% 21% 21% 
Number overdosing in preceding year 46 40 51 54 
Total number answering question 289 302 248 261 
Previously 
in treatment 
Proportion overdosing in preceding year 21% 25% 22% 31% 
Number overdosing in preceding year 59 58 49 82 
Total number answering question 285 236 224 263 
Currently in 
treatment 
Proportion overdosing in preceding year 14% 16% 16% 16% 
Number overdosing in preceding year 177 193 177 188 
Total number answering question 1,277 1,225 1,095 1,152 
a People who reported injecting in the preceding 12 months 
b Prescribed a detox or maintenance drug regime 
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Among recent injectors who had overdosed in the preceding year, half (49%) reported 
overdosing once, and two-fifths (42%) reported overdosing 2-4 times in the last year (table 2). 
5% of those who had overdosed reported it occurring 5-9 times, and 4% reported that they had 
overdosed 10 or more times in the preceding year (table 2). Among survey participants who 
reported overdosing in the preceding year, 47% in 2016 reported having naloxone administered 
(table 2). This is indicative of the availability and use of naloxone but not of its protective value 
since there is no way to know what the outcome of an overdose would have been if naloxone 
had not been administered. In 2016 among those who were currently in treatment for their drug 
use and who reported overdosing in the preceding year, 43% reported having naloxone 
administered. Among those who had previously been in treatment and who reported 
overdosing, 53% reported having naloxone administered (table 2). Treatment status is that  
reported at the time of survey completion and it may have been different at the time of 
overdosing (event occurring during the preceding year).   
 
Table 2. Self-reported naloxone administration by treatment status and frequency of 
overdosing among recent injectorsa who reported non-fatal overdosing in the last year; 
England: 2013-2016 
Year 2013 2014 2015 2016 
All 
Proportion who had naloxone administered 42% 41% 50% 47% 
Number  who had naloxone administered 90 100 114 127 
Total number answering question 216 244 230 270 
Treatment 
b  
status 
Never in 
treatment/ 
not known 
Proportion who had naloxone administered 33% 44% 43% 51% 
Number  who had naloxone administered 12 14 18 20 
Total number answering question 36 32 42 39 
Previously 
in 
treatment 
Proportion who had naloxone administered 51% 46% 63% 53% 
Number  who had naloxone administered 25 22 27 37 
Total number answering question 49 48 43 70 
Currently 
in 
treatment 
Proportion who had naloxone administered 40% 39% 48% 43% 
Number  who had naloxone administered 53 64 69 70 
Total number answering question 131 164 145 161 
Times overdosed  
in the last year  
(proportion) 
1 54% 63% 50% 49% 
2-4 34% 32% 40% 42% 
5-9 7% 4% 7% 5% 
10 or more 5% 2% 4% 4% 
Total number answering question 264 278 268 308 
a People who reported injecting in the preceding 12 months 
b Prescribed a detox or maintenance drug regime  
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Non-fatal overdose is increasing in England, as well as overdose deaths. Half of those 
overdosing in the previous year were administered naloxone. Local areas should commission 
opioid substitution therapy (OST), needle and syringe programmes and take-home naloxone 
and increase efforts  to support more people to engage with and benefit from these services 
and interventions. Older PWID, those who inject multiple drugs, those with a recent overdose, 
and those with co-existing alcohol and mental health problems are all known to be at higher 
risk [1,8]. Additionally, those who have recently been released from prison, discharged from 
hospital or stopped treatment have a lower opioid tolerance and are key risk groups to identify 
and engage in harm reductions interventions and overdose prevention initiatives [8]. 
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